Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Ventyx Biosciences, Inc. Frequently Asked Questions
What is the ticker symbol for Ventyx Biosciences, Inc.? What does VTYX stand for in stocks?
VTYX is the stock ticker symbol of Ventyx Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Ventyx Biosciences, Inc. (VTYX)?
As of Fri Dec 20 2024, market cap of Ventyx Biosciences, Inc. is 158.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of VTYX stock?
You can check VTYX's fair value in chart for subscribers.
Is Ventyx Biosciences, Inc. a good stock to buy?
The fair value guage provides a quick view whether VTYX is over valued or under valued. Whether Ventyx Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ventyx Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTYX.